A comprehensive review on novel delivery approaches for exemestane

Shashank Chaturvedi,Anuj Garg
DOI: https://doi.org/10.1016/j.jddst.2022.103655
IF: 5
2022-09-01
Journal of Drug Delivery Science and Technology
Abstract:Exemestane (EXE) is an irreversible steroidal aromatase inhibitor (AI) approved by the FDA for the treatment of estrogen-dependent breast cancer (EDBC) in post-menopausal women. However, its oral bioavailability is low due to poor aqueous solubility, extensive pre-systemic metabolism, and Para-glycoprotein mediated efflux (P-gp). In the last decade, many novel delivery approaches like lipid-based and polymeric nanoparticles, co-crystals, solid dispersion, and liquid crystalline gel have been explored for enhancing the bioavailability and anti-cancer efficacy of EXE in EDBC. Furthermore, the co-delivery of EXE with some bioactive (polyphenolic phytoestrogens) exhibited a synergistic anti-cancer activity and has the potential to overcome the resistance. Nevertheless, the basement membrane of the milk ducts in the breast acts as a diffusion barrier for systemically administered anti-cancer drugs, and it may reduce the clinical efficacy for EXE. Hence, the major objective of this paper is to critically review all the strategies explored for enhancing the bioavailability and therapeutic efficacy of EXE with their advantages and limitations. Furthermore, the physicochemical and pharmacokinetic properties of EXE have been discussed in-depth to understand the challenges for its successful oral delivery and to design the targeted delivery systems. Additionally, a future perspective about localized transdermal delivery for EXE is also incorporated.
pharmacology & pharmacy
What problem does this paper attempt to address?